1/30
06:07 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/29
07:41 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
1/23
08:04 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
1/12
07:20 am
rlmd
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
1/12
07:00 am
rlmd
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Low
Report
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
12/23
09:37 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Low
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
12/21
08:06 pm
rlmd
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
12/3
07:30 am
rlmd
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Low
Report
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
11/19
09:06 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
11/13
04:20 pm
rlmd
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]
Medium
Report
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]
11/7
07:30 am
rlmd
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Low
Report
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025